David Shulkin Addressed Pharma Executives in Philadelphia
The former VA secretary spoke at the Indegene Digital Summit regarding new drug pricing and AI initiatives.
Updated on Sept. 22, 2026 in Healthcare

Live Poll
Do you trust that direct negotiations between drugmakers and the government will lower consumer costs?
Former VA Secretary David Shulkin addressed pharmaceutical executives at the Indegene Digital Summit in Philadelphia. The discussion highlighted shifting regulatory strategies and new pricing models utilized by the administration.
Why it matters
The current administration is leveraging executive authority to bypass traditional rulemaking as it seeks to lower pharmaceutical drug prices. By engaging directly with manufacturers, officials aim to secure political victories through measurable price reductions.
Proposed models like GLOBE and GUARD apply international pricing data to calculate Medicare drug rebates and costs. The administration maintains a potential reduction threshold of 100% for various pharmaceutical pricing structures.
The players
David Shulkin
He served as the Secretary of Veterans Affairs during the first Trump administration.
AstraZeneca
This global pharmaceutical company participated in the TrumpRx website to list drug prices.
Eli Lilly
This pharmaceutical manufacturer is one of several companies that have listed discounted prices on the TrumpRx platform.
Novo Nordisk
This company is involved in ongoing discussions with federal agencies regarding Medicare drug pricing models.
Pfizer
This pharmaceutical corporation has engaged with federal regulatory shifts to secure favorable payment deals.
The details
The administration is implementing new oversight tools, including the FDA's generative AI tool Elsa, to manage pharmaceutical regulations. Simultaneously, it has encouraged companies like AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer to participate in the TrumpRx website to list discounted drug prices.
Timeline
The FDA launched the generative AI tool named Elsa in 2025.
David Shulkin spoke at the Indegene Digital Summit on Tuesday, September 22, 2026.
Market Landscape
The administration is aggressively pushing new regulatory frameworks to reshape the pharmaceutical competitive environment. By moving beyond the initial scope of the TrumpRx website, the government is forcing manufacturers to adapt to new payment models and oversight tools.
Consumers may see increased transparency and potentially lower costs for specific medications as companies align with new pricing models. However, the reliance on these executive-led negotiations could introduce volatility into standard pharmaceutical pricing and availability.
The takeaway
Pharmaceutical companies are now under increased pressure to monitor CMS payment models and FDA regulatory shifts to remain competitive. Stakeholders should track the rollout of AI tools like Elsa as they will likely influence future drug approval and pricing timelines.
Further reading
For more on the current industry regulatory environment, explore the Healthcare section.
Source note: This article includes information reported by MM+M - Medical Marketing and Media.
Live Poll
Do you trust that direct negotiations between drugmakers and the government will lower consumer costs?






